Novo Nordisk within touching distance of European obesity market as CHMP recommends approval

The EU Committee for Medicinal Products for Human Use has recommended that Novo Nordisk's obesity drug Wegovy be approved. The pharmaceutical company expects to launch the product in Europe in the second half of 2022.

BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN

Novo Nordisk has come one step closer to getting its obesity drug Wegovy approved in Europe, as the CHMP has recommended is approval.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Novo EVP says new data shows Wegovy stands out in obesity crowd
For subscribers
Wegovy weight loss results "very encouraging," says Novo EVP
For subscribers
Raising ambitions at Novo Nordisk an obvious move, says CEO
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Bavarian Nordic submits chikungunya vaccine for approval in Europe

A potential approval of the vaccine could happen in the first half of 2025.

Bavarian Nordic submits vaccine for US approval

Bavarian seeks approval of freeze-dried smallpox vaccine in the US

For subscribers

Novo Nordisk does not have enough capacity to meet the demand for its products. | Foto: Gregers Tycho

Pharma & biotech

Media: Novo Nordisk in talks to buy factory

For subscribers

Photo: M. Spencer Green/AP/Ritzau Scanpix

Pharma & biotech

Innovent and Eli Lilly release weight loss candidate data, plan to compete with Novo in China

Adam Steensberg, CEO, Zealand Pharma | Foto: Stine Bidstrup

Pharma & biotech

Zealand sells USD 1 billion in shares to fund new obesity drugs

For subscribers

Pharma & biotech

Novo Nordisk CEO to testify before senate committee in September

For subscribers

Pharma & biotech

Novo Nordisk sets new record as market value surpasses USD 650bn

UK court gives NHS green light to claim damages against Lundbeck
Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.
For subscribers
Pfizer is testing three new weight loss candidates
Two of the experimental drugs are GLP-1 agents.
For subscribers
Teva to launch generic copy of Novo Nordisk drug in the US
Sales of type 2 diabetes drug Victoza dropped last year.
FDA accepts Lundbeck's application for Rexulti as supplementary PTSD treatment
Lundbeck and partner Otsuka submitted the application in April, and now the FDA will review it for possible approval.
Eli Lilly appoints Nordic Head of Public Affairs
He comes from a position as government affairs director in the Nordics for Vertex Pharmaceuticals and has previously also worked for Novo Nordisk.
For subscribers
Wegovy approved in China
Novo Nordisk’s weight loss drug Wegovy has been approved for the treatment of severe obesity in China.

Pfizer is testing three new weight loss candidates

Two of the experimental drugs are GLP-1 agents.

For subscribers

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.

For subscribers